Blood Pressure Management for Post‑Stroke Secondary Prevention

Target Blood Pressure

Standard target – aim for systolic/diastolic < 140/90 mm Hg in most patients after stroke or TIA. (Grade B/C evidence from the 2018 Hypertension Canada guidelines) 1
Intensive target – consider systolic/diastolic < 130/80 mm Hg for patients with small subcortical infarcts, diabetes, or other very high‑risk features. (Supported by International Journal of Stroke data) 2
Very high‑risk patients – intensive targets are reasonable when recent evidence identifies markedly elevated recurrence risk. (Stroke 2021) 3

ACE‑inhibitor + thiazide (or thiazide‑like) diuretic is the preferred initial regimen for secondary stroke prevention. (Grade B evidence; consistently endorsed across Canadian guidelines) 1
The benefit is derived from the PROGRESS trial, which showed a significant reduction in recurrent stroke with perindopril + indapamide. (Randomized trial evidence) 8

Angiotensin‑receptor blocker (ARB) may replace the ACE inhibitor. (Canadian guideline recommendation) 1
An ARB should be combined with a thiazide (or thiazide‑like) diuretic for comparable blood‑pressure control. (Guideline suggestion) 1

Dihydropyridine calcium‑channel blockers can be added if the target blood pressure is not achieved with the ACE‑inhibitor/diuretic combination. (Canadian guideline, optional) 9
Thiazide diuretics may be used as add‑on therapy (Grade D evidence). (Guideline recommendation) 1

Do not combine an ACE inhibitor with an ARB in post‑stroke patients. (Grade B evidence showing no additional benefit and higher rates of hypotension, hyper‑kalemia, and renal impairment) [4][5]
This recommendation is based on the ONTARGET trial, which included ≈20 % of participants with prior stroke. (Trial data) 7

Start antihypertensive therapy before hospital discharge, after the acute phase (> 72 h post‑stroke). (International Journal of Stroke recommendation) 2
Strong consideration for early initiation is supported by Grade A evidence from multiple Canadian guideline sources. (Guideline consensus) [9][1]4
Avoid routine blood‑pressure lowering in the first 72 h unless systolic > 220 mm Hg or diastolic > 120 mm Hg. (Safety guidance) 1

Frequent monitoring (e.g., monthly) is advised until the target blood pressure is reached and the regimen is stable. (International Journal of Stroke) 2
Routine blood‑pressure measurement should be performed at least annually, with more frequent checks based on clinical circumstances. (Guideline recommendation) 2
Use standardized measurement techniques for office, home, and community settings to ensure accuracy. (Guideline recommendation) 2

Patients receiving thrombolysis – pre‑treatment target < 185/110 mm Hg; post‑treatment (first 24 h) target < 180/105 mm Hg. (Canadian guideline) 1
Intracranial large‑artery atherosclerosis – higher blood‑pressure targets may be needed to preserve cerebral perfusion; avoid excessive lowering that could worsen ischemia. (Stroke 2021 and Canadian guideline) [3][1]
Chronic kidney disease (non‑diabetic) – maintain target < 140/90 mm Hg; if proteinuric, initiate an ACE inhibitor or ARB. (Canadian guideline) 1

Rapid blood‑pressure drops in the acute stroke phase should be avoided by selecting agents and routes that provide gradual reduction. (Safety warning) 1
Combining ACE inhibitor + ARB increases adverse events without added benefit. (Guideline contraindication) [1][4]
Inadequate follow‑up – patients not started on therapy in‑hospital must have arranged outpatient follow‑up with primary‑care or a stroke‑prevention service. (International Journal of Stroke) 2
Neglecting refractory hypertension – requires systematic evaluation for secondary causes. (International Journal of Stroke) 2

The ACE‑inhibitor + thiazide regimen holds the strongest evidence (Grade B) for post‑stroke secondary prevention across Canadian guidelines from 2006‑2018. (Multiple guideline citations) [1][4][5][6]7
The 2021 AHA/ASA guideline also recommends thiazide diuretics, ACE inhibitors, or ARBs with Grade A evidence for reducing recurrent stroke risk. (American guideline) 3